Wire · opportunities
Bausch + Lomb and Celldex rocked by respective phase 2 flops
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Celldex announced stopping development of barzolvolimab in atopic dermatitis after failing phase 2 endpoints despite some benefits, while Bausch + Lomb plans FDA discussions on phase 2 data for BL1332 in post-surgical ocular pain to explore alternative clinical measures for phase 3.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prepare for tougher regulatory discussions on clinical endpoints in pain and skin conditions as FDA dialogues now value patient-meaningful measures over traditional endpoints. Celldex’s halt and Bausch + Lomb’s pivot show that close FDA engagement can keep programs alive despite phase 2 setbacks.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics